Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia

We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Song, Yongping, Zhou, Jian, Fang, Baijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475035/
https://www.ncbi.nlm.nih.gov/pubmed/23044093
http://dx.doi.org/10.1186/1756-8722-5-61
_version_ 1782246887370260480
author Li, Ning
Song, Yongping
Zhou, Jian
Fang, Baijun
author_facet Li, Ning
Song, Yongping
Zhou, Jian
Fang, Baijun
author_sort Li, Ning
collection PubMed
description We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was performed after an interval of one week. All patients achieved clinically significant responses to ATO. The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. So treatment with ATO may be a feasible approach in patients with refractory SAA.
format Online
Article
Text
id pubmed-3475035
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34750352012-10-19 Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia Li, Ning Song, Yongping Zhou, Jian Fang, Baijun J Hematol Oncol Letter to the Editor We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was performed after an interval of one week. All patients achieved clinically significant responses to ATO. The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. So treatment with ATO may be a feasible approach in patients with refractory SAA. BioMed Central 2012-10-09 /pmc/articles/PMC3475035/ /pubmed/23044093 http://dx.doi.org/10.1186/1756-8722-5-61 Text en Copyright ©2012 Li et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Li, Ning
Song, Yongping
Zhou, Jian
Fang, Baijun
Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
title Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
title_full Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
title_fullStr Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
title_full_unstemmed Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
title_short Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
title_sort arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475035/
https://www.ncbi.nlm.nih.gov/pubmed/23044093
http://dx.doi.org/10.1186/1756-8722-5-61
work_keys_str_mv AT lining arsenictrioxideimproveshematopoiesisinrefractorysevereaplasticanemia
AT songyongping arsenictrioxideimproveshematopoiesisinrefractorysevereaplasticanemia
AT zhoujian arsenictrioxideimproveshematopoiesisinrefractorysevereaplasticanemia
AT fangbaijun arsenictrioxideimproveshematopoiesisinrefractorysevereaplasticanemia

Ejemplares similares